Adocia updates on partnership for M1Pram with Sanofi
After markets closed on Friday, French clinical-stage biotech Adocia (Euronext: ADOC) announced the expiration of Sanofi’s (Euronext: SAN) three-year exclusive right to negotiate a partnership agreement for the development of M1Pram.
“Although no GLP-1 therapy is currently approved for type 1 diabetes, the rise of GLP-1 therapies has reshaped the obesity treatment landscape. We will continue to assess the opportunity for M1Pram as new treatments continue to evolve. In the meantime, we are focusing on the development of our metabolic peptide delivery platforms, particularly BioChaperone, the most strategic since it addresses the market’s recent interest in co-formulations and multi-dose formulations,” said Olivier Soula, chief executive co-founder of Adocia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze